| Title |
Oral teicoplanin versus oral vancomycin for the treatment of severe Clostridium difficile infection: a prospective observational study
|
|---|---|
| Published in |
European Journal of Clinical Microbiology & Infectious Diseases, January 2018
|
| DOI | 10.1007/s10096-017-3169-3 |
| Pubmed ID | |
| Authors |
Natasa Popovic, Milos Korac, Zorica Nesic, Branko Milosevic, Aleksandar Urosevic, Djordje Jevtovic, Nikola Mitrovic, Aleksandar Markovic, Jelena Jordovic, Natasa Katanic, Aleksandra Barac, Ivana Milosevic |
| Abstract |
The aim of this study was to compare clinical cure rate, recurrence rate and time to resolution of diarrhea in patients with severe and severe-complicated Clostridium difficile infection (CDI) treated with teicoplanin or vancomycin. This two-year prospective observational study included patients with first episode or first recurrence of CDI who had severe or severe-complicated CDI and were treated with teicoplanin or vancomycin. Primary outcomes of interest were clinical cure rate at discharge and recurrence rate after eight weeks follow up, and secondary outcomes were all-cause mortality and time to resolution of diarrhea. Among 287 study patients, 107 were treated with teicoplanin and 180 with vancomycin. The mean age of patients was 73.5 ± 10.6 years. One hundred eighty six patients (64.8%) had prior CDI episode. Severe complicated disease was detected in 23/107 (21.5%) and 42/180 (23.3%) patients treated with teicoplanin and vancomycin, respectively. There was no statistically significant difference in time to resolution of diarrhea between two treatment arms (6.0 ± 3.4 vs 6.2 ± 3.1 days, p = 0.672). Treatment with teicoplanin resulted in significantly higher clinical cure rate compared to vancomycin [90.7% vs 79.4%, p = 0.013, odds ratio (OR) (95% confidence interval (CI)) 2.51 (1.19-5.28)]. Recurrence rates were significantly lower in patients treated with teicoplanin [9/97 (9.3%) vs 49/143 (34.3%), p < 0.001, OR (95%CI) 0.20 (0.09-0.42)]. There was no statistically significant difference in overall mortality rate. Teicoplanin might be a good treatment option for patients with severe CDI. Patients treated with teicoplanin experienced remarkably lower recurrence rates compared to vancomycin-treated patients. |
X Demographics
The data shown below were collected from the profiles of 104 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 39 | 38% |
| South Africa | 3 | 3% |
| Venezuela, Bolivarian Republic of | 1 | <1% |
| United States | 1 | <1% |
| Mexico | 1 | <1% |
| Unknown | 59 | 57% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 67 | 64% |
| Practitioners (doctors, other healthcare professionals) | 30 | 29% |
| Scientists | 6 | 6% |
| Science communicators (journalists, bloggers, editors) | 1 | <1% |
Mendeley readers
The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 28 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 4 | 14% |
| Other | 3 | 11% |
| Student > Ph. D. Student | 3 | 11% |
| Student > Master | 2 | 7% |
| Student > Doctoral Student | 1 | 4% |
| Other | 6 | 21% |
| Unknown | 9 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 39% |
| Biochemistry, Genetics and Molecular Biology | 3 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 7% |
| Business, Management and Accounting | 1 | 4% |
| Chemical Engineering | 1 | 4% |
| Other | 2 | 7% |
| Unknown | 8 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 68. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 June 2021.
All research outputs
#639,285
of 25,608,265 outputs
Outputs from European Journal of Clinical Microbiology & Infectious Diseases
#32
of 3,104 outputs
Outputs of similar age
#14,593
of 451,803 outputs
Outputs of similar age from European Journal of Clinical Microbiology & Infectious Diseases
#4
of 53 outputs
Altmetric has tracked 25,608,265 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,104 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.7. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 451,803 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 53 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.